Clinical Trials
14
Trial Phases
3 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (10 trials with phase data)• Click on a phase to view related trials
Open Label Trial Studying the Safety and Effectiveness of ILUVIEN® (190μg) in Children and Adolescents, Who Have Recurrent Non-infectious Uveitis Affecting the Posterior Segment of the Eye.
- Conditions
- Non-infectious Uveitis Affecting the Posterior Segment of the Eye
- Interventions
- First Posted Date
- 2024-08-06
- Last Posted Date
- 2024-08-06
- Lead Sponsor
- Alimera Sciences
- Target Recruit Count
- 25
- Registration Number
- NCT06539481
- Locations
- 🇩🇪
Charité - Universitätsmedizin Berlin Institute of Health Department of Ophthalmology, Berlin, Germany
🇩🇪Augenzentrum am St. Franziskus-Hospital Münster, Münster, Germany
🇪🇸Hospital Universitario Cruces, Bilbao, Spain
Fluocinolone Acetonide Intravitreal Implant 0.18 mg in the Treatment of Chronic Non-Infectious Posterior Segment Uveitis
- Conditions
- Uveitis, Posterior
- Interventions
- First Posted Date
- 2022-04-11
- Last Posted Date
- 2024-08-06
- Lead Sponsor
- Alimera Sciences
- Target Recruit Count
- 125
- Registration Number
- NCT05322070
- Locations
- 🇺🇸
Retina Consultants of Orange County, Fullerton, California, United States
🇺🇸Macula and Retina Institute, Glendale, California, United States
🇺🇸California Eye Specialists Medical Group, Pasadena, California, United States
A Study of Intravitreal ILUVIEN® Implant as Baseline Therapy in Patients With Early Diabetic Macular Edema (DME)
- Conditions
- Diabetic Macular Edema
- Interventions
- First Posted Date
- 2020-07-14
- Last Posted Date
- 2024-07-31
- Lead Sponsor
- Alimera Sciences
- Target Recruit Count
- 300
- Registration Number
- NCT04469595
- Locations
- 🇺🇸
Investigative Site, Warrenton, Virginia, United States
A Non-Randomized, Open-Label, Single Center Phase 4 Study of the Effect and Safety of ILUVIEN® in Chronic Diabetic Macular Edema Patients Considered Insufficiently Responsive to Available Therapies (Laser, Anti-VEGF) With or Without Intravitreal Corticosteroid Therapy
- First Posted Date
- 2015-06-15
- Last Posted Date
- 2015-09-16
- Lead Sponsor
- Alimera Sciences
- Target Recruit Count
- 16
- Registration Number
- NCT02472366
Phase 4 IOP Signals Associated With ILUVIEN®
- First Posted Date
- 2015-04-22
- Last Posted Date
- 2022-01-11
- Lead Sponsor
- Alimera Sciences
- Target Recruit Count
- 153
- Registration Number
- NCT02424019
- Locations
- 🇺🇸
Retina Consultants of Arizona, Phoenix, Arizona, United States
🇺🇸Retina Centers, P.C., Tucson, Arizona, United States
🇺🇸Retina and Macula Institute, Glendale, California, United States
- Prev
- 1
- 2
- 3
- Next
News
ILUVIEN Shows Mixed Results in NEW DAY Trial for Diabetic Macular Edema Treatment
ANI Pharmaceuticals' NEW DAY trial of ILUVIEN for diabetic macular edema failed to meet its primary endpoint of reducing supplemental aflibercept injections compared to aflibercept alone (2.4 vs. 2.5 injections, p=0.756).